As earnings season gains momentum, next week’s slate features heavyweights across tech, energy, industrials, and consumer sectors, offering a broad pulse on corporate health and macro conditions.

In a report released on July 17, David Evans from Kepler Capital maintained a Buy rating on Novartis AG, with a price target of CHF106.00. The company’s shares closed yesterday at CHF92.29. Evans ...

As investors navigate through Q2 earnings season, the broader U.S. market ended sideways, bagging a modest gain of 0.45%, ...